Gene Symbol | Pearson Correlation Coefficient |
---|---|
CPT2 | 0.869 |
SLC16A9 | 0.865 |
NPAS3 | 0.863 |
LRP10 | 0.857 |
PBXIP1 | 0.856 |
PLCD1 | 0.855 |
WLS | 0.854 |
ACACB | 0.85 |
STK33 | 0.848 |
MRVI1 | 0.848 |
Gene Symbol | Pearson Correlation Coefficient |
---|---|
AGMAT | -0.448 |
KCNS3 | -0.426 |
TYRP1 | -0.423 |
MCHR1 | -0.419 |
SULT2B1 | -0.417 |
ABCC12 | -0.414 |
QRFPR | -0.413 |
ZNF385D | -0.406 |
LGI2 | -0.398 |
ADRA1D | -0.397 |
ID | Drug Name | Drug Type | CAS Num | Status | Role |
---|---|---|---|---|---|
DB00072 | Trastuzumab | BiotechDrug | 180288-69-1 | Approved|Investigational | Target |
DB01259 | Lapatinib | Small Molecule | 231277-92-2 | Approved|Investigational | Target |
DB04988 | IGN311 | BiotechDrug | - | Investigational | Target |
DB05773 | Trastuzumab emtansine | BiotechDrug | 1018448-65-1 | Approved|Investigational | Target |
DB05944 | Varlitinib | Small Molecule | 845272-21-1 | Investigational | Target |
DB06021 | AV-412 | Small Molecule | 451493-31-5 | Investigational | Target |
DB06366 | Pertuzumab | BiotechDrug | 380610-27-5 | Approved | Target |
DB08916 | Afatinib | Small Molecule | 850140-72-6 | Approved | Target |
DB11652 | Tucatinib | Small Molecule | 937263-43-9 | Investigational | Target |
DB11973 | Tesevatinib | Small Molecule | 781613-23-8 | Investigational | Target |
DB12267 | Brigatinib | Small Molecule | 1197953-54-0 | Approved|Investigational | Target |
ID | Drug Name | Action | PubMed |
---|---|---|---|
C026486 | 1,2,5,6-dibenzanthracene | "1,2,5,6-dibenzanthracene results in decreased expression of ERBB2 mRNA" | 16269432 |
C049325 | 1,2-dithiol-3-thione | "1,2-dithiol-3-thione results in increased expression of ERBB2 mRNA" | 19162173 |
C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | "CTNNB1 gene mutant form affects the susceptibility to [1,4-bis(2-(3,5-dichloropyridyloxy))benzene affects the expression of ERBB2 protein]" | 21705713 |
C033729 | 1H,1H,2H,2H-perfluorodecanol | "1H,1H,2H,2H-perfluorodecanol results in decreased expression of ERBB2 mRNA" | 16393665 |
C508406 | 1H,1H,2H,2H-perfluorooctan-1-ol | "1H,1H,2H,2H-perfluorooctan-1-ol results in decreased expression of ERBB2 mRNA" | 16393665 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "ERBB2 gene mutant form promotes the reaction [PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of AKT1 protein" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of EIF4EBP1 protein" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of FOXO1 protein" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of GSK3B protein" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of RPS6KB1 protein" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of RPS6 protein" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased cleavage of PARP1 protein" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "PIK3CA gene mutant form promotes the reaction [ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]" | 20453058 |
C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "PTEN gene mutant form promotes the reaction [ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]" | 20453058 |
C111118 | 2',3,3',4',5-pentachloro-4-hydroxybiphenyl | "2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ERBB2 mRNA" | 19114083 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein] | 21712253 |
C085911 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] | 12439862 |
C023704 | 2-acetamidoethanethiol | 2-acetamidoethanethiol analog results in decreased activity of and results in decreased phosphorylation of ERBB2 protein | 20058253 |
C049584 | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | "2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ERBB2 mRNA" | 8603490 |
C054649 | 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol | "3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in decreased expression of ERBB2 mRNA" | 12734338 |
C016392 | 3,3'-diindolylmethane | "3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]" | 16580691 |
C016392 | 3,3'-diindolylmethane | "3,3'-diindolylmethane results in decreased phosphorylation of and results in decreased activity of ERBB2 protein" | 16580691 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin] | 21712253 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin] | 21712253 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] | 21712253 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil] | 21712253 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone] | 21712253 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel] | 21712253 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA] | 21712253 |
C434003 | 3-(4-methylphenylsulfonyl)-2-propenenitrile | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein] | 21712253 |
C496751 | 4-(1H-imidazol-1-yl)retinoic acid | 4-(1H-imidazol-1-yl)retinoic acid results in decreased expression of ERBB2 protein | 17145897 |
C433938 | 4557 W | 4557 W results in decreased activity of ERBB2 protein | 17093206 |
C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA" | 27188386 |
C027576 | 4-hydroxy-2-nonenal | 4-hydroxy-2-nonenal results in decreased expression of ERBB2 mRNA | 12419474 |
C041594 | 4-nonylphenol | 4-nonylphenol results in decreased expression of ERBB2 mRNA | 16393665 |
C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA" | 27188386 |
C000601052 | (6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate | "(6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate results in decreased expression of ERBB2 protein" | 25976766 |
C107875 | 6-(methylamino)pyrido(3,4-d)pyrimidine | "6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of ERBB2 protein" | 15572027 |
C020738 | 9,10-dihydro-9,10-dihydroxybenzo(a)pyrene | "9,10-dihydro-9,10-dihydroxybenzo(a)pyrene results in decreased expression of ERBB2 mRNA" | 26238291 |
D000079 | Acetaldehyde | Acetaldehyde affects the expression of ERBB2 mRNA | 22634333 |
D000082 | Acetaminophen | Acetaminophen results in decreased expression of ERBB2 mRNA | 21420995 |
D000082 | Acetaminophen | [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA | 25607892 |
D020106 | Acrylamide | Acrylamide analog results in decreased phosphorylation of ERBB2 protein | 10753475 |
D020106 | Acrylamide | Acrylamide results in decreased expression of ERBB2 mRNA | 28959563 |
D017500 | Adenovirus E1A Proteins | Adenovirus E1A Proteins analog results in decreased expression of ERBB2 protein | 19523934 |
C550911 | ado-trastuzumab emtansine | ado-trastuzumab emtansine binds to and affects the localization of ERBB2 protein | 20730488 |
C550911 | ado-trastuzumab emtansine | ado-trastuzumab emtansine binds to ERBB2 protein | 24035823 |
C550911 | ado-trastuzumab emtansine | ado-trastuzumab emtansine binds to ERBB2 protein | 24035823 |
C016601 | afimoxifene | afimoxifene inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] | 12439862 |
C016601 | afimoxifene | afimoxifene inhibits the reaction [Estrogens results in decreased expression of ERBB2 mRNA] | 21233418 |
C016601 | afimoxifene | ERBB2 results in decreased susceptibility to afimoxifene | 21233418 |
C016601 | afimoxifene | afimoxifene results in increased expression of ERBB2 mRNA | 17640349 |
C081020 | AG-879 | [tyrphostin AG 1478 co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein | 18618485 |
D000393 | Air Pollutants | Air Pollutants analog results in decreased expression of ERBB2 mRNA | 21757418 |
D000584 | Amiloride | Amiloride results in decreased phosphorylation of ERBB2 protein | 16059913 |
D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of ERBB2 mRNA | 16483693 |
D000726 | Androgen Antagonists | [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA | 25607892 |
D000880 | Anthraquinones | Anthraquinones analog results in decreased activity of ERBB2 protein | 27473261 |
D000970 | Antineoplastic Agents | Antineoplastic Agents results in decreased expression of ERBB2 protein | 23125191 |
D000970 | Antineoplastic Agents | Antineoplastic Agents results in decreased expression of ERBB2 protein modified form | 23125191 |
D047310 | Apigenin | [Apigenin co-treated with Fluorouracil] results in decreased expression of ERBB2 protein | 19885610 |
D017638 | Asbestos, Crocidolite | "Asbestos, Crocidolite results in decreased expression of ERBB2 protein" | 15626777 |
D001241 | Aspirin | Aspirin results in decreased expression of ERBB2 mRNA | 19424877 |
D001241 | Aspirin | Aspirin results in decreased expression of ERBB2 protein | 19424877 |
D001241 | Aspirin | Aspirin results in increased expression of ERBB2 mRNA | 20457246 |
C030935 | benz(a)anthracene | benz(a)anthracene results in decreased expression of ERBB2 mRNA | 21635667 |
C022921 | benzo(k)fluoranthene | benzo(k)fluoranthene results in decreased expression of ERBB2 mRNA | 21635667 |
D053119 | Benzophenanthridines | Benzophenanthridines analog results in decreased expression of ERBB2 mRNA | 23117580 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of ERBB2 mRNA | 16269432|2231617 |
D001564 | Benzo(a)pyrene | Benzo(a)pyrene promotes the reaction [AHR protein binds to ERBB2 promoter] | 19654925 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of ERBB2 protein] | 18655187 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB2 protein] | 20332299 |
C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 protein | 20332299 |
D004958 | Estradiol | [Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA | 15072547 |
D004958 | Estradiol | Estradiol promotes the reaction [resveratrol results in increased expression of ERBB2 protein] | 16488535 |
D004958 | Estradiol | Estradiol results in decreased expression of ERBB2 mRNA | 15072547|1639366 |
D004958 | Estradiol | Estradiol results in decreased expression of ERBB2 protein | 16488535 |
D004958 | Estradiol | Estradiol results in increased expression of ERBB2 mRNA | 17555868 |
D004958 | Estradiol | [ERBB2 protein co-treated with ERBB3 protein] results in increased susceptibility to Estradiol | 19861407 |
D004958 | Estradiol | Estradiol results in increased expression of ERBB2 mRNA | 17640349 |
C023888 | beta-hexachlorocyclohexane | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] | 12439862 |
C023888 | beta-hexachlorocyclohexane | afimoxifene inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]] | 12439862 |
C023888 | beta-hexachlorocyclohexane | beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein] | 12439862 |
C023888 | beta-hexachlorocyclohexane | beta-hexachlorocyclohexane results in increased activity of ERBB2 protein | 11222871|9443065 |
C023888 | beta-hexachlorocyclohexane | beta-hexachlorocyclohexane results in increased expression of ERBB2 protein | 12948864 |
C023888 | beta-hexachlorocyclohexane | beta-hexachlorocyclohexane results in increased expression of ERBB2 mRNA | 17640349 |
C006780 | bisphenol A | bisphenol A results in increased expression of ERBB2 mRNA | 29275510 |
C006780 | bisphenol A | bisphenol A results in decreased expression of ERBB2 mRNA | 26063408 |
C006780 | bisphenol A | bisphenol A results in increased phosphorylation of ERBB2 protein | 21988766 |
C006780 | bisphenol A | bisphenol A affects the expression of ERBB2 mRNA | 25181051 |
C006780 | bisphenol A | [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA | 25607892 |
C000611646 | bisphenol F | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA | 28628672 |
D000069286 | Bortezomib | Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein] | 20701607 |
D000069286 | Bortezomib | Bortezomib results in decreased phosphorylation of ERBB2 protein | 20701607 |
D000069286 | Bortezomib | lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] | 20701607 |
C471992 | bosutinib | bosutinib results in decreased phosphorylation of ERBB2 protein | 18385429 |
D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide results in decreased expression of ERBB2 mRNA | 15336504 |
C038091 | butylparaben | [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA | 25607892 |
C018475 | butyraldehyde | butyraldehyde results in decreased expression of ERBB2 mRNA | 26079696 |
C035000 | CAF protocol | ERBB2 protein affects the susceptibility to CAF protocol | 18390970 |
C420268 | Canertinib | Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein] | 18927496 |
D002211 | Capsaicin | Capsaicin affects the expression of ERBB2 mRNA | 19502594 |
D002211 | Capsaicin | Capsaicin results in decreased expression of ERBB2 protein | 19855437 |
D002220 | Carbamazepine | Carbamazepine results in decreased expression of ERBB2 mRNA | 17147113 |
D002220 | Carbamazepine | Carbamazepine results in decreased expression of ERBB2 protein | 16965676 |
D002220 | Carbamazepine | Carbamazepine results in increased degradation of and results in decreased expression of ERBB2 protein | 17147113 |
D002220 | Carbamazepine | Carbamazepine affects the expression of ERBB2 mRNA | 22634333 |
C083924 | CEF regimen | ERBB2 protein affects the susceptibility to CEF regimen | 16707747 |
D002738 | Chloroquine | Chloroquine results in decreased expression of ERBB2 protein | 20332299 |
D002794 | Choline | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA | 20938992 |
C074702 | chromium hexavalent ion | chromium hexavalent ion affects the expression of ERBB2 mRNA | 18053681 |
D003024 | Clozapine | Clozapine affects the phosphorylation of ERBB2 protein | 26961615 |
C034456 | CMF regimen | ERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen] | 18768436 |
C018021 | cobaltous chloride | cobaltous chloride results in decreased expression of ERBB2 mRNA | 19376846 |
D003300 | Copper | Copper results in decreased expression of ERBB2 mRNA | 26293553 |
D003300 | Copper | Copper deficiency results in increased expression of ERBB2 mRNA | 26033743 |
D019327 | Copper Sulfate | Copper Sulfate results in decreased expression of ERBB2 mRNA | 19549813 |
D003375 | Coumestrol | [Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA | 19167446 |
C477330 | CP-654577 | CP-654577 results in decreased activity of ERBB2 protein | 12907618 |
C477330 | CP-654577 | CP-654577 results in decreased phosphorylation of ERBB2 protein | 12907618 |
C516694 | cruentaren A | cruentaren A results in decreased expression of ERBB2 protein | 24450340 |
C030973 | cupric oxide | cupric oxide results in decreased expression of ERBB2 mRNA | 22077320 |
D003471 | Cuprizone | Cuprizone affects the expression of ERBB2 mRNA | 27523638 |
D003471 | Cuprizone | Cuprizone results in increased expression of ERBB2 mRNA | 26577399 |
D003474 | Curcumin | Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Doxorubicin] | 25866362 |
D003474 | Curcumin | Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide] | 25866362 |
D003474 | Curcumin | Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Paclitaxel] | 25866362 |
D003474 | Curcumin | Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein] | 25866362 |
D003474 | Curcumin | Curcumin analog results in decreased expression of ERBB2 mRNA | 17041101|2640932 |
D003474 | Curcumin | Curcumin analog results in decreased expression of ERBB2 protein | 17041101|2586636 |
D003474 | Curcumin | Curcumin analog results in increased degradation of ERBB2 protein | 25866362 |
D003474 | Curcumin | Curcumin promotes the reaction [Fluorouracil results in decreased phosphorylation of and results in decreased expression of and results in decreased activity of ERBB2 protein] | 17918158 |
D003474 | Curcumin | Curcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein] | 17918158 |
D003474 | Curcumin | Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein | 17918158 |
D003474 | Curcumin | Curcumin results in decreased expression of ERBB2 mRNA | 17041101|1871936 |
D003474 | Curcumin | Curcumin results in decreased expression of ERBB2 protein | 17041101|1871936 |
D003474 | Curcumin | ERBB2 protein results in increased susceptibility to Curcumin analog | 25866362 |
D003474 | Curcumin | [ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of AK1 protein | 25866362 |
D003474 | Curcumin | [ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of MAPK1 protein | 25866362 |
D003474 | Curcumin | [ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of MAPK3 protein | 25866362 |
D003474 | Curcumin | Curcumin results in decreased expression of ERBB2 | 18462866 |
D003513 | Cycloheximide | Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein] | 25866362 |
D003513 | Cycloheximide | [Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA | 15072547 |
D003513 | Cycloheximide | Cycloheximide results in decreased expression of ERBB2 mRNA | 15072547|1522809 |
D003513 | Cycloheximide | Cycloheximide results in decreased expression of ERBB2 protein | 20379846 |
D003513 | Cycloheximide | Cycloheximide results in increased degradation of ERBB2 protein | 25866362 |
D003513 | Cycloheximide | PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] | 20379846 |
D003520 | Cyclophosphamide | ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel] | 17010609 |
D003520 | Cyclophosphamide | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel] | 15834928 |
D003520 | Cyclophosphamide | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil] | 15940066 |
D003520 | Cyclophosphamide | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | 9816327 |
D003520 | Cyclophosphamide | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | 16446318|1668272 |
D003520 | Cyclophosphamide | ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] | 16446318 |
D016572 | Cyclosporine | Cyclosporine results in decreased expression of ERBB2 mRNA | 20106945|2556210 |
D003634 | DDT | DDT results in increased phosphorylation of ERBB2 protein | 9070211 |
C017185 | delphinidin | delphinidin results in decreased phosphorylation of ERBB2 protein | 18618485 |
D003847 | Deoxyglucose | [Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein | 18655187 |
D003847 | Deoxyglucose | Deoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
D003907 | Dexamethasone | Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of ERBB2 mRNA] | 27941970 |
D003907 | Dexamethasone | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA | 28628672 |
D016190 | Carboplatin | ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] | 16446318 |
D003993 | Dibutyl Phthalate | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
D003993 | Dibutyl Phthalate | Dibutyl Phthalate results in increased expression of ERBB2 mRNA | 17379624 |
D002945 | Cisplatin | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin] | 21712253 |
D002945 | Cisplatin | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin] | 21712253 |
D002945 | Cisplatin | [Cisplatin co-treated with Fluorouracil] results in decreased expression of ERBB2 mRNA | 15737843 |
D002945 | Cisplatin | Cisplatin results in decreased expression of ERBB2 mRNA | 27392435 |
D002945 | Cisplatin | ERBB2 mRNA results in decreased susceptibility to Cisplatin | 18337622 |
D002945 | Cisplatin | ERBB2 protein affects the susceptibility to Cisplatin | 10327070 |
D002945 | Cisplatin | ERBB2 results in decreased susceptibility to Cisplatin | 21712253 |
D002945 | Cisplatin | [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Cisplatin | 21712253 |
D003633 | Dichlorodiphenyl Dichloroethylene | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
C036042 | dicyclohexyl phthalate | dicyclohexyl phthalate affects the expression of ERBB2 mRNA | 26924002 |
D004051 | Diethylhexyl Phthalate | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
D004054 | Diethylstilbestrol | Diethylstilbestrol results in increased expression of ERBB2 protein | 16439099 |
C024629 | dimethyl phthalate | dimethyl phthalate affects the expression of ERBB2 mRNA | 26924002 |
C067311 | docetaxel | ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel] | 17010609 |
C067311 | docetaxel | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel] | 15834928 |
C067311 | docetaxel | ERBB2 protein results in increased susceptibility to docetaxel | 15567936 |
D004317 | Doxorubicin | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin] | 21712253 |
D004317 | Doxorubicin | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin] | 21712253 |
D004317 | Doxorubicin | ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin] | 21712253 |
D004317 | Doxorubicin | Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Doxorubicin] | 25866362 |
D004317 | Doxorubicin | Doxorubicin affects the expression of ERBB2 mRNA | 15205334 |
D004317 | Doxorubicin | ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel] | 17010609 |
D004317 | Doxorubicin | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel] | 15834928 |
D004317 | Doxorubicin | ERBB2 protein affects the susceptibility to Doxorubicin | 10327070 |
D004317 | Doxorubicin | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | 9816327 |
D004317 | Doxorubicin | ERBB2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein] | 16168102 |
D004317 | Doxorubicin | ERBB2 protein results in decreased susceptibility to Doxorubicin | 25467193|2586636 |
D004317 | Doxorubicin | ERBB2 results in decreased susceptibility to Doxorubicin | 21712253 |
D004317 | Doxorubicin | [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Doxorubicin | 21712253 |
D004317 | Doxorubicin | NFE2L2 protein affects the reaction [ERBB2 protein results in decreased susceptibility to Doxorubicin] | 25467193 |
D004317 | Doxorubicin | [TOP2A protein co-treated with ERBB2 protein] results in increased susceptibility to Doxorubicin | 15486187 |
D004317 | Doxorubicin | NRG1 protein affects the reaction [Doxorubicin affects the phosphorylation of ERBB2 protein] | 15833803 |
D004317 | Doxorubicin | Doxorubicin promotes the reaction [HSP90AA1 protein binds to ERBB2 protein] | 17308081 |
D004317 | Doxorubicin | Doxorubicin results in increased expression of ERBB2 protein | 17308081 |
D004317 | Doxorubicin | ERBB2 protein promotes the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in decreased expression of TNNI3 protein]] | 19801490 |
D004317 | Doxorubicin | ERBB2 protein promotes the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in decreased expression of TNNT2 protein]] | 19801490 |
D000068538 | Dutasteride | Dutasteride results in increased expression of ERBB2 mRNA | 17636412 |
C038939 | enzacamene | [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA | 25607892 |
D015251 | Epirubicin | ERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen] | 18768436 |
D015251 | Epirubicin | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | 16446318|1668272 |
C045651 | epigallocatechin gallate | epigallocatechin gallate results in decreased phosphorylation of ERBB2 protein | 18618485 |
C109476 | epoxiconazole | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
D004967 | Estrogens | afimoxifene inhibits the reaction [Estrogens results in decreased expression of ERBB2 mRNA] | 21233418 |
D004967 | Estrogens | Estrogens results in decreased expression of ERBB2 mRNA | 21233418 |
D004967 | Estrogens | Estrogens results in increased expression of ERBB2 mRNA | 14647453 |
C032773 | ethyl caffeate | ethyl caffeate affects the expression of ERBB2 protein | 24892518 |
C032773 | ethyl caffeate | ethyl caffeate affects the phosphorylation of and affects the activity of ERBB2 protein | 24892518 |
D005038 | Ethylnitrosourea | Ethylnitrosourea results in increased mutagenesis of ERBB2 gene | 16651423 |
D005047 | Etoposide | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] | 21712253 |
D005047 | Etoposide | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] | 21712253 |
D005047 | Etoposide | ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] | 21712253 |
D005047 | Etoposide | Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide] | 25866362 |
D005047 | Etoposide | ERBB2 protein affects the susceptibility to Etoposide | 10327070 |
D005047 | Etoposide | ERBB2 protein results in decreased susceptibility to Etoposide | 25866362 |
D005047 | Etoposide | ERBB2 results in decreased susceptibility to Etoposide | 21712253 |
D005047 | Etoposide | [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide | 21712253 |
D005047 | Etoposide | Etoposide results in decreased expression of ERBB2 mRNA | 15228094 |
C052498 | FEC protocol | ERBB2 protein promotes the reaction [TOP2A protein results in increased susceptibility to FEC protocol] | 16682728 |
C020748 | ferrous sulfate | ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
C020748 | ferrous sulfate | ferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein] | 18655187 |
D005395 | Fish Oils | Fish Oils results in decreased activity of ERBB2 protein | 15867269 |
D015073 | 2-Acetylaminofluorene | 2-Acetylaminofluorene results in increased expression of ERBB2 protein | 11350689 |
D005472 | Fluorouracil | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil] | 21712253 |
D005472 | Fluorouracil | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil] | 21712253 |
D005472 | Fluorouracil | ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil] | 21712253 |
D005472 | Fluorouracil | [Apigenin co-treated with Fluorouracil] results in decreased expression of ERBB2 protein | 19885610 |
D005472 | Fluorouracil | [Cisplatin co-treated with Fluorouracil] results in decreased expression of ERBB2 mRNA | 15737843 |
D005472 | Fluorouracil | Curcumin promotes the reaction [Fluorouracil results in decreased phosphorylation of and results in decreased expression of and results in decreased activity of ERBB2 protein] | 17918158 |
D005472 | Fluorouracil | ERBB2 mRNA results in decreased susceptibility to Fluorouracil | 18337622 |
D005472 | Fluorouracil | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil] | 15940066 |
D005472 | Fluorouracil | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | 9816327 |
D005472 | Fluorouracil | ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] | 16446318|1668272 |
D005472 | Fluorouracil | ERBB2 results in decreased susceptibility to Fluorouracil | 21712253 |
D005472 | Fluorouracil | [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Fluorouracil | 21712253 |
D005472 | Fluorouracil | Fluorouracil affects the expression of ERBB2 mRNA | 15205334 |
D005472 | Fluorouracil | Fluorouracil results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein | 17918158 |
C410216 | Folfox protocol | Curcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein] | 17918158 |
C410216 | Folfox protocol | Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein | 17918158 |
D005492 | Folic Acid | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA | 20938992 |
C070081 | fulvestrant | ERBB2 affects the susceptibility to fulvestrant | 24169358 |
C070081 | fulvestrant | fulvestrant results in increased expression of ERBB2 mRNA | 15072547 |
C039281 | furan | furan results in increased expression of ERBB2 mRNA | 27387713 |
C419708 | gefitinib | gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein] | 17898861 |
C419708 | gefitinib | gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein] | 17898861 |
C419708 | gefitinib | gefitinib results in decreased phosphorylation of ERBB2 protein | 16243822 |
C001277 | geldanamycin | [geldanamycin binds to HSP90B1 protein] inhibits the reaction [HSP90B1 protein binds to ERBB2 protein] | 8617772 |
C001277 | geldanamycin | geldanamycin inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
C001277 | geldanamycin | geldanamycin results in decreased expression of and results in increased ubiquitination of ERBB2 protein | 18655187 |
C001277 | geldanamycin | geldanamycin results in decreased expression of ERBB2 protein | 24450340 |
C001277 | geldanamycin | geldanamycin results in increased degradation of ERBB2 protein | 11071886|1795951 |
C001277 | geldanamycin | Quercetin promotes the reaction [geldanamycin results in decreased expression of and results in increased ubiquitination of ERBB2 protein] | 18655187 |
C001277 | geldanamycin | geldanamycin results in decreased activity of ERBB2 protein | 15254267 |
D005947 | Glucose | [Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein | 18655187 |
D005947 | Glucose | Glucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
C506645 | GW2974 | GW2974 results in decreased activity of ERBB2 protein | 19352663 |
C551538 | GW 583340 | GW 583340 results in decreased phosphorylation of ERBB2 protein | 28426875 |
D006220 | Haloperidol | Haloperidol results in increased expression of and results in increased phosphorylation of ERBB2 protein | 26961615 |
D006534 | Heptachlor Epoxide | Heptachlor Epoxide results in increased activity of ERBB2 protein | 11222871 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide affects the expression of ERBB2 mRNA | 20044591 |
D006861 | Hydrogen Peroxide | Hydrogen Peroxide results in decreased expression of ERBB2 mRNA | 12419474 |
C475919 | hydroxytamoxifen | hydroxytamoxifen results in decreased expression of ERBB2 mRNA | 15072547 |
C041508 | indeno(1,2,3-cd)pyrene | "indeno(1,2,3-cd)pyrene results in decreased expression of ERBB2 mRNA" | 21635667 |
D007213 | Indomethacin | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA | 28628672 |
C051890 | irinotecan | irinotecan affects the expression of ERBB2 mRNA | 20097248 |
D015056 | 1-Methyl-3-isobutylxanthine | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA | 28628672 |
C098607 | JP8 aviation fuel | JP8 aviation fuel results in decreased expression of ERBB2 protein | 17337753 |
C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in decreased expression of ERBB2 mRNA | 25961927 |
C456099 | KF58333 | KF58333 results in decreased expression of ERBB2 protein | 11800023 |
C490728 | lapatinib | Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein] | 20701607 |
C490728 | lapatinib | ERBB2 protein affects the reaction [lapatinib results in decreased activity of MAPK1 protein] | 25221644 |
C490728 | lapatinib | ERBB2 protein affects the reaction [lapatinib results in decreased activity of MAPK3 protein] | 25221644 |
C490728 | lapatinib | ERBB2 protein affects the reaction [lapatinib results in decreased expression of CCND1 protein] | 25221644 |
C490728 | lapatinib | ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein] | 25221644 |
C490728 | lapatinib | lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] | 20701607 |
C490728 | lapatinib | lapatinib results in decreased activity of ERBB2 protein | 15665275|1719253 |
C490728 | lapatinib | lapatinib results in decreased expression of ERBB2 protein | 16091755 |
C490728 | lapatinib | lapatinib results in decreased phosphorylation of ERBB2 protein | 20701607|2664360 |
C490728 | lapatinib | [lapatinib results in decreased susceptibility to lapatinib] which results in increased phosphorylation of ERBB2 protein | 26643609 |
C490728 | lapatinib | lapatinib results in decreased phosphorylation of ERBB2 protein | 20197467 |
C490728 | lapatinib | lapatinib results in decreased activity of ERBB2 protein | 16091755 |
D007854 | Lead | Lead results in decreased expression of ERBB2 mRNA | 19921347 |
D017705 | Lignans | Lignans results in decreased expression of ERBB2 protein | 15897583 |
D008043 | Linseed Oil | Linseed Oil results in decreased expression of ERBB2 mRNA | 19904759 |
D008043 | Linseed Oil | Linseed Oil results in decreased expression of ERBB2 protein | 19904759 |
D008043 | Linseed Oil | Linseed Oil results in decreased phosphorylation of ERBB2 protein | 19904759 |
D008043 | Linseed Oil | Linseed Oil results in decreased expression of ERBB2 protein | 21138602 |
D008043 | Linseed Oil | Linseed Oil results in decreased phosphorylation of ERBB2 protein | 21138602 |
D008044 | Linuron | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
D009637 | Masoprocol | Masoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of ERBB2 protein] | 18645000 |
D008466 | Mechlorethamine | Mechlorethamine results in decreased expression of ERBB2 protein | 17932452 |
D015122 | Mercaptopurine | Mercaptopurine results in decreased expression of ERBB2 mRNA | 23358152 |
D008715 | Methionine | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA | 20938992 |
D008727 | Methotrexate | ERBB2 protein affects the susceptibility to Methotrexate | 10327070 |
D008727 | Methotrexate | Methotrexate results in increased expression of ERBB2 mRNA | 21678067 |
D008769 | Methylnitronitrosoguanidine | Methylnitronitrosoguanidine results in increased expression of ERBB2 mRNA | 12634122 |
D008942 | Mitoxantrone | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone] | 21712253 |
D008942 | Mitoxantrone | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone] | 21712253 |
D008942 | Mitoxantrone | ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone] | 21712253 |
D008942 | Mitoxantrone | ERBB2 results in decreased susceptibility to Mitoxantrone | 21712253 |
D008942 | Mitoxantrone | [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Mitoxantrone | 21712253 |
C406082 | monomethylarsonous acid | monomethylarsonous acid results in increased phosphorylation of ERBB2 protein | 17093206 |
C517284 | monomethyl phthalate | monomethyl phthalate affects the expression of ERBB2 mRNA | 26924002 |
C523799 | MRK 003 | MRK 003 results in decreased expression of ERBB2 mRNA | 21169257 |
C570404 | N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide | "N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide results in decreased activity of ERBB2 protein" | 22003817 |
C000621033 | napabucasin | napabucasin results in decreased expression of ERBB2 mRNA | 25605917 |
C119536 | nickel acetate | nickel acetate results in increased phosphorylation of ERBB2 protein | 25053108 |
D009588 | Nitrogen Mustard Compounds | Nitrogen Mustard Compounds results in decreased expression of ERBB2 mRNA | 16417271 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | "ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 mRNA]" | 21823616 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | "ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 protein]" | 21823616 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | "N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 mRNA" | 21823616 |
C562238 | N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide | "N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 protein" | 21823616 |
C516714 | NVP-TAE684 | [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein] which results in decreased susceptibility to NVP-TAE684 | 22843788 |
C118580 | octylmethoxycinnamate | [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA | 25607892 |
C440229 | Oleylethanolamide | Oleylethanolamide promotes the reaction [ERBB2 protein binds to MAP2K1 protein modified form] | 16269455 |
C440229 | Oleylethanolamide | Oleylethanolamide promotes the reaction [ERBB2 protein binds to MAP2K2 protein modified form] | 16269455 |
C440229 | Oleylethanolamide | Oleylethanolamide promotes the reaction [ERBB2 protein binds to MAPK1 protein modified form] | 16269455 |
C440229 | Oleylethanolamide | Oleylethanolamide promotes the reaction [ERBB2 protein binds to MAPK3 protein modified form] | 16269455 |
C440229 | Oleylethanolamide | Oleylethanolamide results in increased phosphorylation of ERBB2 protein | 16269455 |
D015525 | Fatty Acids, Omega-3 | "Fatty Acids, Omega-3 results in decreased activity of ERBB2 protein" | 15867269 |
C507134 | ON 01910 | ON 01910 results in increased phosphorylation of ERBB2 protein | 25472472 |
C016340 | o,p'-DDT | "o,p'-DDT results in increased activity of ERBB2 protein" | 11222871|9443065 |
C055122 | orlistat | ERBB2 protein affects the susceptibility to orlistat | 15870086 |
C055122 | orlistat | orlistat affects the localization of ERBB2 protein | 15870086 |
C055122 | orlistat | orlistat results in decreased expression of ERBB2 mRNA | 15870086 |
C055122 | orlistat | orlistat results in decreased expression of ERBB2 protein | 15870086 |
D017239 | Paclitaxel | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel] | 21712253 |
D017239 | Paclitaxel | "3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]" | 16580691 |
D017239 | Paclitaxel | 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel] | 21712253 |
D017239 | Paclitaxel | Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Paclitaxel] | 25866362 |
D017239 | Paclitaxel | ERBB2 protein affects the susceptibility to Paclitaxel | 10327070 |
D017239 | Paclitaxel | ERBB2 protein results in decreased susceptibility to Paclitaxel | 25866362 |
D017239 | Paclitaxel | ERBB2 results in decreased susceptibility to Paclitaxel | 21712253 |
D017239 | Paclitaxel | [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel | 21712253 |
D017239 | Paclitaxel | Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein | 16580691 |
D017239 | Paclitaxel | ERBB2 protein results in decreased susceptibility to Paclitaxel | 16580691 |
D010269 | Paraquat | ERBB2 protein results in decreased susceptibility to Paraquat | 25467193 |
D010269 | Paraquat | NFE2L2 protein affects the reaction [ERBB2 protein results in decreased susceptibility to Paraquat] | 25467193 |
D052638 | Particulate Matter | Particulate Matter results in increased expression of ERBB2 mRNA | 28412507 |
D020135 | Peptide Nucleic Acids | Peptide Nucleic Acids results in decreased expression of ERBB2 mRNA | 16417271 |
C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in decreased expression of ERBB2 mRNA | 18692542 |
C023036 | perfluorooctanoic acid | perfluorooctanoic acid results in decreased expression of ERBB2 protein | 26879310 |
D026023 | Permethrin | Permethrin results in increased activity of ERBB2 protein | 11222871 |
D010662 | Phenylmercuric Acetate | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA" | 27188386 |
D010662 | Phenylmercuric Acetate | Phenylmercuric Acetate results in decreased expression of ERBB2 mRNA | 26272509 |
C027260 | pirarubicin | ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil] | 15940066 |
C410026 | PKI 166 | PKI 166 results in decreased activity of ERBB2 protein | 15377668 |
D010936 | Plant Extracts | Plant Extracts results in decreased expression of ERBB2 protein | 20482751 |
C045362 | prochloraz | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
C035988 | procymidone | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
D011441 | Propylthiouracil | Propylthiouracil results in increased expression of ERBB2 mRNA | 24780913 |
D011794 | Quercetin | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of ERBB2 protein] | 18655187 |
D011794 | Quercetin | [Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein | 18655187 |
D011794 | Quercetin | Deoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
D011794 | Quercetin | ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
D011794 | Quercetin | ferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein] | 18655187 |
D011794 | Quercetin | geldanamycin inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
D011794 | Quercetin | [Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein | 18655187 |
D011794 | Quercetin | Glucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] | 18655187 |
D011794 | Quercetin | Quercetin inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein] | 12888923 |
D011794 | Quercetin | Quercetin inhibits the reaction [TGFA protein results in increased phosphorylation of ERBB2 protein] | 12888923 |
D011794 | Quercetin | Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein] | 18655187 |
D011794 | Quercetin | Quercetin promotes the reaction [geldanamycin results in decreased expression of and results in increased ubiquitination of ERBB2 protein] | 18655187 |
D011794 | Quercetin | Quercetin promotes the reaction [ST13 protein modified form binds to and results in increased ubiquitination of ERBB2 protein] | 18655187 |
D011794 | Quercetin | Quercetin results in decreased expression of and results in decreased phosphorylation of ERBB2 protein | 12888923 |
D011794 | Quercetin | Quercetin results in decreased expression of ERBB2 protein | 15741050 |
D011794 | Quercetin | Quercetin results in decreased phosphorylation of ERBB2 protein | 18655187 |
D011794 | Quercetin | Quercetin results in increased expression of ERBB2 mRNA | 14715546 |
D011794 | Quercetin | ST13 protein modified form affects the reaction [Quercetin results in increased ubiquitination of ERBB2 protein] | 18655187 |
D011794 | Quercetin | Quercetin results in increased ubiquitination of ERBB2 protein | 21750559 |
D011799 | Quinazolines | Quinazolines analog results in decreased phosphorylation of ERBB2 protein | 10753475 |
D020849 | Raloxifene Hydrochloride | ERBB2 protein results in decreased susceptibility to Raloxifene Hydrochloride | 16609042 |
D012110 | Reserpine | ERBB2 protein results in increased susceptibility to Reserpine | 8093862 |
C059514 | resveratrol | [Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA | 19167446 |
C059514 | resveratrol | EGF protein inhibits the reaction [resveratrol results in decreased phosphorylation of ERBB2 protein] | 20729295 |
C059514 | resveratrol | Estradiol promotes the reaction [resveratrol results in increased expression of ERBB2 protein] | 16488535 |
C059514 | resveratrol | resveratrol results in decreased expression of ERBB2 | 15688416 |
C059514 | resveratrol | resveratrol results in decreased expression of ERBB2 mRNA | 25448084 |
C059514 | resveratrol | resveratrol results in decreased expression of ERBB2 protein | 16488535|2544808 |
C059514 | resveratrol | resveratrol results in decreased phosphorylation of ERBB2 protein | 20729295 |
C059514 | resveratrol | resveratrol results in increased expression of ERBB2 mRNA | 16488535 |
C059514 | resveratrol | resveratrol results in increased expression of ERBB2 protein | 16488535 |
C059514 | resveratrol | resveratrol results in decreased expression of ERBB2 | 15688416 |
C020491 | rhein | rhein results in decreased expression of ERBB2 protein | 21457705 |
D018967 | Risperidone | Risperidone results in increased phosphorylation of ERBB2 protein | 26961615 |
C087123 | romidepsin | romidepsin results in decreased expression of ERBB2 protein | 15014036 |
C090142 | secoisolariciresinol diglucoside | secoisolariciresinol diglucoside results in decreased expression of ERBB2 protein | 19904759 |
C090142 | secoisolariciresinol diglucoside | secoisolariciresinol diglucoside results in decreased phosphorylation of ERBB2 protein | 19904759 |
D012643 | Selenium | [Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA | 19244175 |
D012643 | Selenium | Selenium results in increased expression of ERBB2 mRNA | 19244175 |
D012822 | Silicon Dioxide | Silicon Dioxide analog results in decreased expression of ERBB2 mRNA | 25895662 |
C017947 | sodium arsenite | ERBB2 mutant form inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] | 15734884 |
C017947 | sodium arsenite | sodium arsenite affects the expression of ERBB2 protein | 17384772 |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of and results in increased activity of ERBB2 protein | 15734884 |
C017947 | sodium arsenite | sodium arsenite results in increased phosphorylation of ERBB2 protein | 20043101 |
C017947 | sodium arsenite | tyrphostin AG825 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of ERBB2 protein] | 15734884 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of ERBB2 mRNA | 11241755 |
C025462 | sulindac sulfide | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB2 protein] | 20332299 |
C025462 | sulindac sulfide | sulindac sulfide results in decreased expression of ERBB2 protein | 20332299 |
C025463 | sulindac sulfone | sulindac sulfone results in decreased expression of ERBB2 protein | 20332299 |
D013629 | Tamoxifen | ERBB2 protein inhibits the reaction [PA2G4 protein results in increased susceptibility to Tamoxifen] | 20379846 |
D013629 | Tamoxifen | ERBB2 protein results in decreased susceptibility to Tamoxifen | 15665275|1600058 |
D013629 | Tamoxifen | [ERBB2 protein results in increased activity of ESR1 protein] which results in decreased susceptibility to Tamoxifen | 20179226 |
D013629 | Tamoxifen | Tamoxifen results in increased phosphorylation of ERBB2 protein | 17157789 |
D013629 | Tamoxifen | Tamoxifen results in increased expression of ERBB2 protein | 21138602 |
D013629 | Tamoxifen | Tamoxifen results in increased phosphorylation of ERBB2 protein | 21138602 |
C112765 | tanespimycin | tanespimycin results in increased degradation of and results in decreased expression of ERBB2 protein | 16061882 |
C020806 | tetrabromobisphenol A | tetrabromobisphenol A results in increased expression of ERBB2 mRNA | 26353976 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of ERBB2 mRNA | 22298810|2257421 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of ERBB2 mRNA | 26238291 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA | 11162886|1755586 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ERBB2 promoter] | 19654925 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA | 21215274 |
C005806 | tetrachloroisophthalonitrile | tetrachloroisophthalonitrile results in increased activity of ERBB2 protein | 11222871 |
D013755 | Tetradecanoylphorbol Acetate | PIN1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ERBB2 protein] | 20479004 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased expression of ERBB2 protein | 20479004 |
D013792 | Thalidomide | [ERBB2 protein co-treated with PIK3CA protein mutant form] results in increased susceptibility to Thalidomide metabolite | 28745489 |
D013852 | Thiotepa | ERBB2 protein affects the susceptibility to Thiotepa | 10327070 |
D013852 | Thiotepa | ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] | 16446318 |
C009495 | titanium dioxide | titanium dioxide results in decreased expression of ERBB2 mRNA | 23409001 |
D014212 | Tretinoin | Tretinoin results in decreased expression of ERBB2 mRNA | 21934132 |
D014212 | Tretinoin | Tretinoin results in decreased expression of ERBB2 protein | 16752155 |
D014212 | Tretinoin | HBEGF protein promotes the reaction [Tretinoin results in increased phosphorylation of ERBB2 protein] | 16357442 |
D014212 | Tretinoin | Tretinoin results in increased phosphorylation of ERBB2 protein | 16357442 |
D014241 | Trichloroethylene | Trichloroethylene results in decreased expression of ERBB2 mRNA | 15363585 |
C015559 | trimellitic anhydride | trimellitic anhydride results in decreased expression of ERBB2 mRNA | 19042947 |
C101044 | tyrphostin AG 1478 | [tyrphostin AG 1478 co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein | 18618485 |
C098214 | tyrphostin AG825 | tyrphostin AG825 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of ERBB2 protein] | 15734884 |
C098214 | tyrphostin AG825 | tyrphostin AG825 results in decreased activity of and results in decreased phosphorylation of ERBB2 protein | 20058253 |
C098214 | tyrphostin AG825 | tyrphostin AG825 results in decreased activity of ERBB2 protein | 15254267 |
C022884 | undecane | undecane results in decreased expression of ERBB2 protein | 17337753 |
D014520 | Urethane | Urethane results in decreased expression of ERBB2 mRNA | 28818685 |
D014635 | Valproic Acid | Valproic Acid affects the expression of ERBB2 mRNA | 25979313 |
D014635 | Valproic Acid | Valproic Acid results in decreased expression of ERBB2 mRNA | 23179753|2800136 |
D001335 | Vehicle Emissions | Vehicle Emissions results in decreased methylation of ERBB2 gene | 25560391 |
D014747 | Vinblastine | ERBB2 protein affects the susceptibility to Vinblastine | 10327070 |
C025643 | vinclozolin | [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA | 25607892 |
D014810 | Vitamin E | [Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA | 19244175 |
C111237 | vorinostat | vorinostat results in decreased expression of ERBB2 mRNA | 27188386 |
C111237 | vorinostat | vorinostat results in decreased expression of ERBB2 protein | 17218635 |
C111237 | vorinostat | vorinostat results in increased ubiquitination of and results in increased degradation of and results in decreased expression of ERBB2 protein | 16144943 |
GO ID | GO Term | Qualifier | Evidence | PubMed |
---|---|---|---|---|
GO:0001042 | RNA polymerase I core binding | - | IDA | 21555369 |
GO:0004709 | MAP kinase kinase kinase activity | - | IBA | 21873635 |
GO:0004713 | protein tyrosine kinase activity | - | IBA | 21873635 |
GO:0004713 | protein tyrosine kinase activity | - | IDA | 7556068 |
GO:0004713 | protein tyrosine kinase activity | - | IGI | 7556068 |
GO:0004713 | protein tyrosine kinase activity | - | TAS | - |
GO:0004714 | transmembrane receptor protein tyrosine kinase activity | - | IBA | 21873635 |
GO:0004714 | transmembrane receptor protein tyrosine kinase activity | - | IDA | 7514177 |
GO:0004888 | transmembrane signaling receptor activity | - | IBA | 21873635 |
GO:0004888 | transmembrane signaling receptor activity | - | IDA | 7514177 |
GO:0005088 | Ras guanyl-nucleotide exchange factor activity | - | TAS | - |
GO:0005515 | protein binding | - | IPI | 7592681 9079677 9705354 10572067 10805725 11067847 11940572 12061724 12122014 12975581 15657067 16273093 16314522 16516204 16729043 16767099 16843263 17148612 17426253 18719096 19167335 19372587 19411071 19650109 19933325 20010870 20227043 20558745 20700126 20876300 21034468 21075308 21203579 21255571 21278786 21376233 21555369 21724847 21840311 22279592 22589551 22733765 22806884 22939624 23436906 23680147 23688700 23866081 23995768 24189400 24412244 24557338 24658140 24815698 25036637 25081058 25241761 25326665 25640309 26517842 |
GO:0005524 | ATP binding | - | IEA | - |
GO:0008022 | protein C-terminus binding | - | IPI | 15520177 |
GO:0019838 | growth factor binding | contributes_to | IDA | 7514177 |
GO:0019903 | protein phosphatase binding | - | IPI | 15899872 |
GO:0031434 | mitogen-activated protein kinase kinase binding | - | IBA | 21873635 |
GO:0042802 | identical protein binding | - | IPI | 16843263 17148612 19650109 21203579 21255571 21480528 22733765 23436906 |
GO:0043125 | ErbB-3 class receptor binding | - | TAS | 9590694 |
GO:0046934 | phosphatidylinositol-4,5-bisphosphate 3-kinase activity | - | TAS | - |
GO:0046982 | protein heterodimerization activity | - | IDA | 10572067 |
GO:0046982 | protein heterodimerization activity | - | IPI | 7556068 |
GO:0046983 | protein dimerization activity | - | NAS | 12000754 |
GO ID | GO Term | Qualifier | Evidence | PubMed |
---|---|---|---|---|
GO:0000165 | MAPK cascade | - | TAS | - |
GO:0001934 | positive regulation of protein phosphorylation | - | ISS | - |
GO:0006351 | transcription, DNA-templated | - | IEA | - |
GO:0006357 | regulation of transcription by RNA polymerase II | - | TAS | - |
GO:0006468 | protein phosphorylation | - | TAS | 10851066 |
GO:0007165 | signal transduction | - | IDA | 10572067 |
GO:0007166 | cell surface receptor signaling pathway | - | IDA | 9685399 |
GO:0007167 | enzyme linked receptor protein signaling pathway | - | TAS | 9590694 |
GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | - | IDA | 7514177 |
GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | - | TAS | 7556068 |
GO:0007275 | multicellular organism development | - | IBA | 21873635 |
GO:0007422 | peripheral nervous system development | - | IEA | - |
GO:0007507 | heart development | - | IEA | - |
GO:0007528 | neuromuscular junction development | - | IEA | - |
GO:0008045 | motor neuron axon guidance | - | IEA | - |
GO:0008283 | cell proliferation | - | TAS | 10851066 |
GO:0009968 | negative regulation of signal transduction | - | IBA | 21873635 |
GO:0014065 | phosphatidylinositol 3-kinase signaling | - | IDA | 7556068 |
GO:0018108 | peptidyl-tyrosine phosphorylation | - | IEA | - |
GO:0030154 | cell differentiation | - | IBA | 21873635 |
GO:0030307 | positive regulation of cell growth | - | IMP | 21555369 |
GO:0032886 | regulation of microtubule-based process | - | IDA | 20937854 |
GO:0033088 | negative regulation of immature T cell proliferation in thymus | - | IEA | - |
GO:0033674 | positive regulation of kinase activity | - | IBA | 21873635 |
GO:0038128 | ERBB2 signaling pathway | - | TAS | - |
GO:0042060 | wound healing | - | IDA | 12646923 |
GO:0042552 | myelination | - | IEA | - |
GO:0043066 | negative regulation of apoptotic process | - | IBA | 21873635 |
GO:0043406 | positive regulation of MAP kinase activity | - | IDA | 10572067 |
GO:0043410 | positive regulation of MAPK cascade | - | IBA | 21873635 |
GO:0043547 | positive regulation of GTPase activity | - | ISS | - |
GO:0045727 | positive regulation of translation | - | IMP | 21555369 |
GO:0045765 | regulation of angiogenesis | - | NAS | 15609325 |
GO:0045785 | positive regulation of cell adhesion | - | IDA | 7556068 |
GO:0045943 | positive regulation of transcription by RNA polymerase I | - | IMP | 21555369 |
GO:0045945 | positive regulation of transcription by RNA polymerase III | - | IDA | 19372587 |
GO:0046777 | protein autophosphorylation | - | IDA | 7556068 |
GO:0046854 | phosphatidylinositol phosphorylation | - | IEA | - |
GO:0048709 | oligodendrocyte differentiation | - | IEA | - |
GO:0050679 | positive regulation of epithelial cell proliferation | - | IDA | 10572067 |
GO:0051897 | positive regulation of protein kinase B signaling | - | TAS | - |
GO:0070372 | regulation of ERK1 and ERK2 cascade | - | IMP | 16314522 |
GO:0070374 | positive regulation of ERK1 and ERK2 cascade | - | IBA | 21873635 |
GO:0071363 | cellular response to growth factor stimulus | - | IDA | 20010870 |
GO:0071364 | cellular response to epidermal growth factor stimulus | - | IMP | 27134172 |
GO:0090314 | positive regulation of protein targeting to membrane | - | IDA | 20010870 |
GO:1901185 | negative regulation of ERBB signaling pathway | - | TAS | - |
GO:2000145 | regulation of cell motility | - | TAS | - |
GO ID | GO Term | Qualifier | Evidence | PubMed |
---|---|---|---|---|
GO:0005634 | nucleus | - | IDA | 16314522 21555369 |
GO:0005737 | cytoplasm | - | IBA | 21873635 |
GO:0005829 | cytosol | - | IDA | - |
GO:0005886 | plasma membrane | - | IDA | 20010870 |
GO:0005886 | plasma membrane | - | NAS | 12000754 |
GO:0005886 | plasma membrane | - | TAS | - |
GO:0005887 | integral component of plasma membrane | - | IBA | 21873635 |
GO:0009925 | basal plasma membrane | - | IBA | 21873635 |
GO:0010008 | endosome membrane | - | IDA | 16314522 |
GO:0016021 | integral component of membrane | - | NAS | 15609325 |
GO:0016323 | basolateral plasma membrane | - | IDA | 12646923 |
GO:0016324 | apical plasma membrane | - | IEA | - |
GO:0043209 | myelin sheath | - | IEA | - |
GO:0043235 | receptor complex | - | IBA | 21873635 |
GO:0043235 | receptor complex | - | IDA | 7514177 23382219 |
GO:0043235 | receptor complex | - | TAS | 7556068 |
GO:0048471 | perinuclear region of cytoplasm | - | IEA | - |
KEGG ID | KEGG Term |
---|---|
hsa04012 | ErbB signaling pathway |
hsa04020 | Calcium signaling pathway |
hsa04510 | Focal adhesion |
hsa04520 | Adherens junction |
hsa05200 | Pathways in cancer |
hsa05212 | Pancreatic cancer |
hsa05213 | Endometrial cancer |
hsa05215 | Prostate cancer |
hsa05219 | Bladder cancer |
hsa05223 | Non-small cell lung cancer |
Reactome ID | Reactome Term | Evidence |
---|---|---|
R-HSA-1227986 | Signaling by ERBB2 | TAS |
R-HSA-1227986 | Signaling by ERBB2 | IEA |
R-HSA-1250196 | SHC1 events in ERBB2 signaling | IEA |
R-HSA-1250196 | SHC1 events in ERBB2 signaling | TAS |
R-HSA-1251932 | PLCG1 events in ERBB2 signaling | IEA |
R-HSA-1257604 | PIP3 activates AKT signaling | TAS |
R-HSA-1266738 | Developmental Biology | TAS |
R-HSA-1306955 | GRB7 events in ERBB2 signaling | TAS |
R-HSA-1358803 | Downregulation of ERBB2:ERBB3 signaling | TAS |
R-HSA-162582 | Signal Transduction | TAS |
R-HSA-162582 | Signal Transduction | IEA |
R-HSA-1643685 | Disease | TAS |
R-HSA-1963640 | GRB2 events in ERBB2 signaling | IEA |
R-HSA-1963640 | GRB2 events in ERBB2 signaling | TAS |
R-HSA-1963642 | PI3K events in ERBB2 signaling | TAS |
R-HSA-199418 | Negative regulation of the PI3K/AKT network | TAS |
R-HSA-212436 | Generic Transcription Pathway | TAS |
R-HSA-2219528 | PI3K/AKT Signaling in Cancer | TAS |
R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | TAS |
R-HSA-373755 | Semaphorin interactions | TAS |
R-HSA-400685 | Sema4D in semaphorin signaling | TAS |
R-HSA-416572 | Sema4D induced cell migration and growth-cone collapse | TAS |
R-HSA-422475 | Axon guidance | TAS |
R-HSA-5663202 | Diseases of signal transduction | TAS |
R-HSA-5673001 | RAF/MAP kinase cascade | TAS |
R-HSA-5683057 | MAPK family signaling cascades | TAS |
R-HSA-5684996 | MAPK1/MAPK3 signaling | TAS |
R-HSA-6785631 | ERBB2 Regulates Cell Motility | TAS |
R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | TAS |
R-HSA-73857 | RNA Polymerase II Transcription | TAS |
R-HSA-74160 | Gene expression (Transcription) | TAS |
R-HSA-8847993 | ERBB2 Activates PTK6 Signaling | TAS |
R-HSA-8848021 | Signaling by PTK6 | TAS |
R-HSA-8863795 | Downregulation of ERBB2 signaling | TAS |
R-HSA-8864260 | Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | TAS |
R-HSA-8866910 | TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | TAS |
R-HSA-9006925 | Intracellular signaling by second messengers | TAS |
R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases | TAS |
R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | TAS |
R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | IEA |
PMID | Title (Year) | Author | Journal |
---|---|---|---|
27262212 | Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug) | Noonan SA | J Thorac Oncol |
17164260 | Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. (2007 Jan 15) | Einarsdottir K | Hum Mol Genet |
21455582 | Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. (2011 Jun) | Santini D | Oncol Rep |
21316260 | Targeting phosphoinositide 3-kinase signalling in lung cancer. (2011 Nov) | Wojtalla A | Crit Rev Oncol Hematol |
20832392 | MUC1 expression and its association with other aetiological factors and localization to mitochondria in preneoplastic and neoplastic gastric tissues. (2010 Dec 14) | Benjamin JB | Clin Chim Acta |
25351745 | MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15) | Arcila ME | Clin Cancer Res |
29511884 | Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma. (2018 May) | Nakasone S | J Cancer Res Clin Oncol |
23744164 | The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy. (2013) | Nicos M | Pneumonol Alergol Pol |
9445135 | Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. (1998 Jan) | Fleming MV | Hum Pathol |
28753770 | Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. (2016 Jun 24) | Joshi M | Eur Urol Focus |
16003726 | EGFR and erbB2 mutation status in Japanese lung cancer patients. (2006 Jan 1) | Sasaki H | Int J Cancer |
24137397 | Keap1 mutations in lung cancer patients. (2013 Sep) | Sasaki H | Oncol Lett |
26200269 | Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug) | Shim HS | J Thorac Oncol |
25738220 | Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May) | Sholl LM | J Thorac Oncol |
23723294 | Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep) | Dearden S | Ann Oncol |
14581353 | Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. (2003 Oct 15) | Miller CT | Clin Cancer Res |
26873401 | Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. (2016 May) | Sawada G | Gastroenterology |
23991993 | B-cell Lymphoma 2 rs17757541 C>G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. (2013) | Li Q | Asian Pac J Cancer Prev |
28472989 | Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. (2017 May 4) | Yang M | J Hematol Oncol |
28169993 | The evolving genomic landscape of urothelial carcinoma. (2017 Feb 7) | Glaser AP | Nat Rev Urol |
23303019 | Expression of Epidermal Growth Factor (EGF) and its receptors (EGFR1 and EGFR2) in chronic bronchitis. (2012) | Marinas AE | Rom J Morphol Embryol |
19046792 | Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. (2009 Jul) | Lopez-Malpartida AV | Lung Cancer |
27939360 | Cellular and molecular mechanisms underlying alcohol-induced aggressiveness of breast cancer. (2017 Jan) | Wang Y | Pharmacol Res |
20604875 | ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. (2010 Nov) | Silva SD | Oral Dis |
27565922 | Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep) | Maki-Nevala S | Lung Cancer |
19690778 | Malignant fibrous histiocytoma of larynx with giant cell: case report and histological-clinical considerations. (2009) | Anghelina F | Rom J Morphol Embryol |
15563701 | Expression of ErbB receptors and mucins in the airways of long term current smokers. (2004 Dec) | O'Donnell RA | Thorax |
25007143 | Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec) | Boland JM | Am J Surg Pathol |
24278325 | Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. (2013) | Urashima M | PLoS One |
19690148 | Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. (2009 Sep 1) | Ohashi K | Cancer Res |
16865253 | Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. (2006 Sep) | Endo K | Oncol Rep |
24137465 | Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system. (2013 Oct) | Krawczyk P | Oncol Lett |
25567908 | Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15) | Drilon A | Clin Cancer Res |
29217530 | The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). (2018 Mar 1) | Aisner DL | Clin Cancer Res |
22969966 | Braf and erbB2 mutations correlate with smoking status in lung cancer patients. (2012 May) | Sasaki H | Exp Ther Med |